Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV axis 1 psychiatric comorbidity (dual diagnosis)

European Addiction Research

Volumn 14, Issue 3, 2008, Pages 134-142

  Maremmani, Icro ^a,b,c,h   Pacini, Matteo ^a,c   Lubrano, Sonia ^a   Perugi, Giulio ^a,c   Tagliamonte, Alessandro ^d   Pani, Pier Paolo ^e   Gerra, Gilberto ^f   Shinderman, Marc ^g  

^a UNIVERSITY OF PISA   (Italy)

^b AU CNS   (Italy)

^c G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e Sardinia Health and Social Administration   (Italy)

^f United Nations Office on Drugs and Crime Austria   (Austria)

^g Center for Addictive Problems   (United States)

^h UNIVERSITY OF PISA   (Italy)

Author keywords

Dual diagnosis; High threshold program; Long term outcome; Methadone maintenance

Indexed keywords

METHADONE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEROIN DEPENDENCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; CATCHMENT AREA (HEALTH); COHORT STUDIES; COMORBIDITY; DEMOGRAPHY; DIAGNOSIS, DUAL (PSYCHIATRY); DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG RESISTANCE; FEMALE; HEROIN DEPENDENCE; HIV INFECTIONS; HUMANS; ITALY; MALE; MENTAL DISORDERS; METHADONE; NARCOTICS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RETENTION (PSYCHOLOGY); TIME FACTORS; TREATMENT FAILURE;

EID: 45249104871     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000130417     Document Type: Article

References (46)

1. Dole VP, Nyswander ME: A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965;193:80-84.
2. Ball JC, Ross CA: The Effectiveness of Methadone Maintenance Treatment. New York, Springer, 1991.
3. Grönbladh L, Öhlund LS, Gunne LM: Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 1990;82:223-227.
4. Schottenfeld RS, Kleber HD: Methadone maintenance; in Kaplan HD, Sadock BJ (eds): Comprehensive Textbook of Psychiatry. Baltimore, Williams & Wilkins, 1995.
5. Lowinson J, Marion I, Joseph H, Dole V: Methadone maintenance; in Lowinson J, Ruiz P, Millman R, Langrod J (eds): Substance Abuse: A Comprehensive Textbook. Baltimore, Williams & Wilkins, 1992, pp 550-561.
6. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Cochrane Review); in The Cochrane Library, issue 4. Oxford, Update Software, 2002.
7. Strain EC, Bigelow GE, Liebson IA, Stitzer ML: Moderate- versus high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999;281:1000-1005.
8. Substance Abuse and Mental Health Services Administration: 2002 National Survey on Drug Use and Health. Rockville, Office of Applied Studies, 2003, NHSDA Series H-21, DHHS Publ No SMA 03-3774.
9. Carpenter MD, Mulligan JC, Bader IA, Meinzer AE: Multiple admissions to an urban psychiatric center: a comparative study. Hosp Commun Psychiatry 1985;36:1305-1308.
10. Casper ES, Romo JM, Fasnacht RC: Readmission patterns of frequent users of inpatient psychiatric services. Hosp Commun Psychiatry 1991;42:1166-1169.
11. Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner R, Burns BJ: Violence and severe mental illness: the effect of substance abuse and nonadherence to medication. Am J Psychiatry 1998;155:226-231.
12. Keck PE, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM, Bourne ML, Haggard P: Twelve-mount outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998;55:646-652.
13. Salloum IM, Delay DC, Cornelius JR, Kirisci L, Thase ME: Disproportional lethality in psychiatric patients with concurrent alcohol and cocaine abuse. Am J Psychiatry 1996;153:953-955.
14. Mueser T, Bellak AS, Blanchard JJ: Comorbidity in schizophrenia and substance abuse: implication for treatment. J Consult Clin Psychol 1992;60:845-856.
15. Clark RE: Family costs associated with severe mental illness and substance abuse. Hosp Commun Psychiatry 1994;45:808-813.
16. Cuffel BJ, Chase P: Remission and relapse of substance use disorders in schizophrenia: results from a one-year prospective study. J Nerv Ment Dis 1994;182:342-348.
17. Farrell M, Howes S, Taylor C, Lewis G, Jenkins R, Bebbington P, Jarvis M, Brugha M, Gill B, Meltzer H: Substance misuse and psychiatric comorbidity: an overview of the OPCS national psychiatric morbidity survey. Addict Behav 1998;23:909-918.
18. Maremmani I, Perugi G, Pacini M, Akiskal H: Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 2006;93:1-12.
19. Schifano F, Bargagli AM, Belleudi V, Amato L, Davoli M, Diecidue R, Versino E, Vigna-Taglianti F, Faggiano F, Perucci CA: Methadone treatment in clinical practice in Italy: need for improvement. Eur Addict Res 2006;12:121-127.
20. D'Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM: Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend 1998;52:167-171.
21. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P: Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003;3.
22. Maremmani I, Castrogiovanni P: DAH-RS: Drug Addiction History Rating Scale. Pisa, University Press, 1989.
23. APA: Diagnostic and Statistical Manual of Mental Disorders, DSM-IV. Washington, American Psychiatric Association, 1994.
24. AA.VV.: Clinical Global Impressions; in Guy W (ed): ECDEU Assessment Manual for Psychopharmacology. Rockville, US Department of Health, Education & Welfare, 1976, pp 218-222.
25. Cassano GB, Akiskal HS, Musetti L, Perugi G, Soriani A, Mignani V: Psychopathology, temperament and paste course in primary mayor depression: toward a redifinition of bipolarity with a new semistructured interview for depression. Psychopathology 1989;22:278-288.
26. Akiskal HS, Mallya G: Criteria for the 'soft' bipolar spectrum: treatment implications. Psychopharmacol Bull 1987;23:68-73.
27. Schneider K: Psychopathic Personalities. Springfield, Thomas, 1958.
28. Perugi G, Musetti L, Simonini E, Piagentini F, Cassano GB, Akiskal HS: Gender mediated clinical features of depressive illness: the importance of temperamental differences. Br J Psychiatry 1990;157:835-841.
29. Perugi G, Akiskal HS, Micheli C, Musetti L, Paiano A, Quilici C, Rossi L, Cassano GB: Clinical subtypes of bipolar mixed states: validating a broader European definition in 143 cases. J Affect Disord 1997;43:169-180.
30. Dole VP, Joseph H: Long term outcome of patients treated with methadone maintenance. Ann NY Acad Sci 1978;311:181-189.
31. Siassi I, Angle BP, Alston DC: Comparison of the effect of high and low doses of methadone on treatment outcome. Int J Addict 1977;12:993-1005.
32. Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Methadone dose and treatment outcome. Drug Alcohol Depend 1993;33:105-117.
33. Foster DJ, Somogyi AA, Bochner F: Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-412.
34. Änggård E: Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 1974;17:258-266.
35. Verebely K, Volavka J, Mule S, Resnick R: Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975;18:180-190.
36. Wilkinson GR: Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996;24:475-490.
37. Goodwin B, Redimbo MR, Kliewer SA: Regulation of CYP3A gene transcription by the Pregnane X receptor. Ann Rev Pharmacol Toxicol 2002;42:1-23.
38. Brady KT, Sonne SC: The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995;56:19-24.
39. Maremmani I, Zolesi O, Aglietti M, Marini G, Tagliamonte A, Shinderman MS, Maxwell S: Methadone dose and retention in treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis 2000;19:29-41.
40. Pani PP, Trogu E, Contu P, Agus A, Gessa GL: Psychiatric severity and treatment response in a comprehensive methadone maintenance treatment program. Drug Alcohol Depend 1997;48:119-126.
41. Cacciola SJ, Alterman AI, Rutherford MJ, McKay JR, Mulvaney FD: The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 2001;61:271-280.
42. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S: Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004;75:37-45.
43. Gelkopf M, Weizman T, Melamed Y, Adelson M, Bleich A: Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Isr J Psychiatry Relat Sci 2006;43:126-136.
44. Fernandez Miranda J, Gonzalez Garcia-Portilla M, Saiz Martinez P, Gutierrez Cienfuegos E, Bobes Garcia J: Influence of psychiatric disorders in the effectiveness of a long-term methadone maintenance treatment. Actas Esp Psiquiatr 2001;29:228-232.
45. Rounsaville BJ, Cacciola J, Weissman MM, Kleber HD: Diagnostic concordance in a follow-up study of opiate addicts. J Psychiatr Res 1981;16:191-201.
46. Rounsaville BJ, Weissman MM, Kleber H, Wilber C: Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982;39:161-166.